You are here

Home » Content

Evre 1 ve Evre 2 Sarkoidoz ile Tüberküloz Lenfadenit Hastalıklarının Ayırıcı Tanısında QuantiFERON–TB GOLD (in Tube) Testinin Rolü

Usefulness of the QuantiFERON-TB GOLD (in Tube) Test for the Differantial Diagnosis of Sarcoidosis from Tuberculosis Lymphadenitis

Journal Name:

  • Abant Tıp Dergisi

Publication Year:

  • 2017
DOI: 
10.5505/abantmedj.2017.42275

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
INTRODUCTION: There is one of the new methods in the differential diagnosis QuantiFERON-TB Gold (in tube) (QFTGIT), in which the most common cause of sarcoidosis and tuberculosis lymphadenitis of benign mediastinal lymphadenopathy, we aimed to investigate the value of the test for TB lymphadenitis. METHODS: Chest CT transverse diameter of 10 mm and directed to our clinic to investigate the etiology of mediastinal lymph nodes above sarcoidosis was diagnosed in 36 patients with TB lymphadenitis was diagnosed in 37 patients, including 73 patients age, sex, comorbid disease, the tuberculosis contact history, symptoms, number of BCG scar, TST and QFTGIT results were recorded test results. RESULTS: The mean age of patients with sarcoidosis 42.2± 17.2) were female (52.8%), 17 were male (47.2%). Average follow-up time was 14.6 ± 12.3 months. (3-36 months). With sarcoidosis, which is still being used in the differential diagnosis of TB lymphadenitis, TCT's sensitivity in diagnosis of TB lymphadenitis was 62%, specificity 75%; QFT-GIT sensitivity of the test was 92%, specificity of 83% was calculated. Sarcoidosis QFT-GIT and TST test results of there were no significant correlation between [p = 0.618]; Significant correlation was found for TB lymphadenitis [p = 0.028]. DISCUSSION AND CONCLUSION: As our country and communities of routine BCG vaccination should be vaccinated again applied according to TST results, BCG also affected in the differential diagnosis of tuberculosis infection, QFT-GIT be recommended for use with the TST test. Also planned patients receiving systemic steroid therapy for starting INH prophylaxis be taken into account rather than the TST positive QFT-GIT test may be appropriate.
Bookmark/Search this post with
Abstract (Original Language): 
GİRİŞ ve AMAÇ: Mediastinal benign lenfadenopatinin en sık nedenleri sarkoidoz ve tüberküloz lenfadenit hastalıklarıdır. Çalışmamızda, TB lenfadenitin ayırıcı tanısında yeni yöntemlerden birisi olan QuantiFERON–TB Gold (in tube) (QFTGIT) testinin değerini araştırmayı amaçladık. YÖNTEM ve GEREÇLER: Toraks BT’de transvers çapı 10 mm ve üzerinde olan mediastinal lenf nodlarının etiyolojisinin araştırılması amacıyla kliniklerimize yönlendirilerek 36’sı sarkoidoz ve 37’si TB lenfadenit tanısı konulan toplam 73 hastanın prospektif olarak yaş, cinsiyet, eşlik eden ek hastalık, tüberküloz temas öyküsü, semptomları, BCG skar sayısı, TCT sonuçları ve QFT-GIT testi sonuçları kaydedildi. BULGULAR: Sarkoidoz hastalarının yaş ortalamaları 42,2±17,2 idi. Olguların 19’u kadın (%52.8), 17’si erkekti (% 47,2). Ortalama takip süreleri 14,6±12,3 ay idi (3 – 36 ay). Sarkoidoz ile TB lenfadenit ayırıcı tanısında halen kullanılmakta olan TCT nin, TB lenfadenit tanısında duyarlılığı %62, özgüllüğü %75; QFT-GIT testinin duyarlılığı %92, özgüllüğü %83 olarak hesaplandı. Sarkoidozda QFT-GIT testi ve TCT sonuçları arasında anlamlı korelasyon bulunmazken [p=0,618]; TB lenfadenit için anlamlı korelasyon saptandı [p=0,028]. TARTIŞMA ve SONUÇ: Ülkemizde olduğu gibi rutin BCG aşılamasının ve TCT sonucuna göre yeniden aşılanmaların uygulandığı topluluklarda, tüberküloz enfeksiyonun ayırıcı tanısında BCG den etkilenmeyen QFT-GIT testinin TCT ile birlikte kullanılması önerilebilir. Ayrıca sistemik steroid tedavisi alması planlanan hastalarda INH proflaksisi başlanması için tek başına TCT’den ziyade QFT-GIT testi pozitifliğinin gözönüne alınması uygun olabilir.
FULL TEXT (PDF): 
PDF icon arastirmax-evre-1-evre-2-sarkoidoz-ile-tuberkuloz-lenfadenit-hastaliklarinin-ayirici-tanisinda-quantiferon-tb-gold-tube-testinin-rolu.pdf
  • 3
93
99
  • Turkish

REFERENCES

References: 

1. Hunninghake GW, Costabel V,Ando M,et al.ATS / ERS /
WASOG statement of sarcoidosis.Sarcoidosis Vasc.Diffuse
Lung Dis.1999; 16; 149-55
2. Cortez K, Kottilil S, Mermel LA. Intracerebral tuberculoma
misdiagnosed as neurosarcoidosis. South Med J
2003;96:494-6.
3. Hatzakis K, Siafakas NM, Bouros D. Miliary sarcoidosis
following miliary tuberculosis. Respiration 2000; 67:219-
22.
4. Gupta D, Chetty M, Kumar N, et al. Anergy to tuberculin
in sarcoidosis is not influenced by high prevalence of
tuberculin sensitivity in the population. Sarcoidosis
Vasc Diffuse Lung Dis 2003;20:40-5.
5. Gurkan Ural O, Celik G, Kumbasar O ,Kaya A, Alper D,
Sarcoidosis in Turkey; 1954-2000 Ann Saudi Med
2004;36-9.
6. Litinsky I, Elkayam O, Flusser G. Sarcoidosis: TB or not
TB? Annals of the Rheumatic Diseases, 2002; 61: 385-
386.
7. Burton B J, Breen R A; Janossy G. Use of İnterferon
gamma Responses to Mycobacterial Antigen to
Distinguish Sarcoid Associated Optic Neuropathy From
Tuberculosis. Br J Ophthalmol, 2006 Jun; 90(6): 802-3.
8. Jiang J,Shi H,Liang Q,Qin S,Qin X.Diagnostic value of
interferon gama in tuberculous Pleurisy. Ametaanaliz.
Chest 2007;131:1133-41.
9. Tabak L, Kılıçarslan Z, Kıyan E ve ark. 147 sarkoidoz
hastasının klinik özellikleri. Solunum 2001;3:80-5.
10. Baran A, Özşeker F. Sarkoidoz: Yedi Yıllık Deneyim. Toraks
Dergisi, 2004 Aralık; Cilt5 Sayı3: Sayfa160-165.
11. Dandapat MC, Mishra BM, Dash SP, Kar PK.Peripheral
lymph node tuberculosis: a review of 80 cases. Br J Surg
1990;77:911-2.
12. Jasmer RM, Nahid P, Hopewell PC. Clinical practice.
Latent tuberculosis infection. N Engl J Med 2002; 347:
1860-6.
13. Pai M, Riley LW, Colford JM., Jr Interferon-gamma assays
in the immunodiagnosis of tuberculosis: a systematic
review. Lancet Infect Dis. 2004;4:761–776.
14. Kik SV, Franken WP, Mensen M, Cobelens FG, Kamphorst
M, et al. Predictive value for progression to tuberculosis
by IGRA and TST in immigrant contacts. Eur Respir J
(epub) 2009;35(6):1346–53.
15. Lienhardt C, Fielding K, Hane AA, Niang A, Ndao CT, et al.
Evaluation of the prognostic value of IFN-gamma release
assay and tuberculin skin test in household contacts of
infectious tuberculosis cases in Senegal. PLoS One. 2010;
5:e10508.
16. Centers for Disease Control and Prevention.Updated
guidelines for using interferon gama release assays to
detect mycobacterium tuberculosis infection- United
States ,2010. MMWR 2010;59:1-26.
17. T.C Sağlık Bakanlığı tüberküloz tanı ve tedavi rehberi,
Ankara 2011,ek 3 :tüberkülin deri testi ve ek 4 : interferon
gama salınım testleri;113-122.
18. Seyhan E, Gunluoglu G, Gunluoglu MZ, Tural S and Sökücü
S.Predictive value of the tuberculin skin test and
QuantiFERON-tuberculosis Gold In-Tube test for
development of active tuberculosis in hemodialysis
patients.Ann Thorac Med. 2016 Apr-Jun; 11(2): 114–120.
19. Inui N, Suda T, Chida X. Use of the QuantiFERON TB Gold
test in Japanese patients with sarcoidosis. Respir Med.
2008;102:313- 5.
20. Gupta D, Kumar S, Aggarwal AN, Verma I, Agarwal R.
Interferon Gamma Release Assay QuantiFERON TB Gold
in Tube in patients of Sarcoidosis from a population with
prevalence of tuberculosis infection. Sarcoidosis Vasc
Diffuse Lung Dis. 2011;28:95 - 101.
21. Vyas S, Thangakunam B, Gupta R, Michael JS, Christopher
DJ. Interferon gamma release assay and tuberculin skin
test positivity in sarcoidosis.Lung India.2015 Jan-Feb;
32(1): 91-92.
22. Legesse M, Ameni G, Mamo G, Medhin G, Bjune G and
Abebe F. Performance of QuantiFERON-TB Gold In-Tube
(QFTGIT) for the diagnosis of Mycobacterium tuberculosis
infection in Afar Pastoralists, Ethiopia. BMC Infect Dis.
2010; 10: 354.
23. Xia H, Wang X,Li F,Longuet C, Vernet G,Goletti D,Zhao Y
and Lagrange PH. Diagnostic Values of the QuantiFERONTB
Gold In-Tube Assay Carried out in China for Diagnosing
Pulmonary Tuberculosis. PLoS One. 2015; 10(4):
e0121021.
24. Mahomed H,Hawkridge T, Verver S, Abrahams D, Geiter
L,Hatherill M, Ehrlich R. The Tuberculin Skin Test versus
QuantiFERON TB Gold in Predicting Tuberculosis Disease
in an Adolescent Cohort Study in South Africa. PLoS One.
2011; 6(3): e17984.

Thank you for copying data from http://www.arastirmax.com